Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

4) To exclude the forgiveness of a mortgage loan by the Pennsylvania

Industrial Development Board ("PIDA").

(5) To reflect the tax effect of pre-tax adjustments at the applicable

tax rates and certain other tax adjustments primarily related to

changes in valuation allowances and other changes in tax assets and

liabilities.

(6) To exclude the U.S. Department of Defense ("DoD") Tricare program

reversal as a result of the U.S. Court of Appeals September 2006

ruling.

(7) To exclude charges associated with the settlement of the PROVIGIL

patent litigation.

(8) Amounts shown no longer exclude the impact of Financial Accounting

Standards Board Statement No. 123(R) "Share Based Payment" ("SFAS

123(R)"). The earnings press release issued on November 2, 2006

reflected adjustments of $3.4 million in each of Research and

development and Selling, general and administrative expenses and $2.8

million in Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2007 2006

GAAP NET INCOME (LOSS) $(235,886) $149,725

Sales adjustments - (13,273)(7)

Cost of sales adjustments 64,236 (1) 69,375 (1)

Research and development adjustments 41,500 (2) 45,000 (2) (11)

Selling, general and administrative

adjustments - 9,987 (8) (11)

Settlement reserve 425,000 (3) -

Impairment charge
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...rille, Inc.,(OTC Bulletin Board: FVRL) and MyMedi...n company focused on secure Web-based storage of e...ed today that two significant conditions,required...ent have been met. , (Logo: http://www.ne... "We are pleased to announce that Favrille cred...
(Date:12/4/2008)...wire/ -- Octapharma,Chairman Wolfgang Marguerre t...ected to lead Octapharma,s plasma operations in th.... legal counsel since 2002 and will now serve as,...largest private plasma products company in the wor...s, the Atlanta company that operates 12,plasma ce...
(Date:12/4/2008)...-- AC Immune SA, a leader,in Alzheimer,s disease ...Economic Forum has elected AC Immune as Technology...ation leader and for its breakthrough technologies...ety. , Furthermore, AC Immune released that...n the development of innovative therapies against ...
(Date:12/4/2008)...mune today announced that,it has initiated a Phas... to,determine the safety of subcutaneous dosing o...ets the interleukin-5 receptor (IL-5R). Preclinica...may lead to a targeted approach for,treating pati...is antibody. , "Asthma can be a very debili...
Breaking Biology Technology:Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3
... Main Menu , , , , , , ...ND PROGRAMS. PRESS ENTER TO SELECT HIGHLIGHTED CHO...ioning cursor to the choice desired, then press ,...ta or changes display to next menu in hierarchy. ,...ss enter) , Position cursor to choose progra...
... From MAIN MENU go to FILES/ EDIT/ , STA...to choose)/ ENTER/ , change name to BIGDYE/... , , , , ..., , , Pa... , , Explanation ...
... 7.6.5 PCR "Fingerprinting" (RAPD-PCR) , ...hich can be programmed as desired with , ea...ature-control speed to be aligned to the temperatu...r with PCR with A/T-rich primer/template hybrids, ...arefully after annealing. , , In th...
... Joel Lopez and Vincent Prezioso, , PhD...ments Inc., Westbury, New York, , , ,...underwent revolutionary changes during the 1980,s,... One of the most significant changes was inspired ... which the amplification of specific , be...
Other Biology Technology:Mastercycler Gradient Quick Programming Guide 2Eppendorf Mastercycler ABI Big Dye Sequencing Protocol 2Eppendorf Mastercycler ABI Big Dye Sequencing Protocol 3Eppendorf Mastercycler ABI Big Dye Sequencing Protocol 4Two-step Gradient PCR* 2Two-step Gradient PCR* 3Two-step Gradient PCR* 4Two-step Gradient PCR* 5Two-step Gradient PCR* 6
(Date:12/3/2008)...ooking at the site today, it,s easy to forget that...ty of Wisconsin-Madison,s Franbrook Farm Research ...he structure are gone, and acres of plants, both n...r basin. , Nevertheless, memories of the dam rem...W-Madison researchers are now unearthing them. Wri...
(Date:12/3/2008)... Mo. "FORE"...Though they may not help improve a ...e the way golfers think about the local country cl...of Missouri study. , "There are more than 17,000...ely 70 percent of that land is not used for playin...logy in the MU College of Arts and Science. "These...
(Date:12/3/2008)...ell-known fact in drug trials that individuals can... to the active drug. On the other hand, it is dif...er from placebos. A team of researchers from Upps...found gene variants that can impact the placebo ef...es those who respond to placebos. , The study, p...
(Date:12/3/2008)..., IL, December 3, 2008 Today, the International S... leading professional organization of stem cell re...ible development of safe and effective stem cell t...ummarizes the Guidelines for the Clinical Translat...in the December issue of Cell Stem Cell , the off...
Breaking Biology News(10 mins):Researchers examine role of soil patterns in dam restoration 2Researchers examine role of soil patterns in dam restoration 3Golf course: Playing fields, wildlife sanctuaries or both 2Genes determine whether sugar pills work 2The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Rochester Medical Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 21665 1Rochester Medical Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 21665 2Rochester Medical Honored by Premier Healthcare Alliance for Exceeding Performance Expectations 21665 3Neogen Plans to Double R 26D Staff Efforts 5959 1Neogen Plans to Double R 26D Staff Efforts 5959 2Invention to prevent surgical adhesions wins Kaye Award 21662 1Invention to prevent surgical adhesions wins Kaye Award 21662 2Adalimumab therapy effective in AS RA and PsA patients refractory to other anti TNF therapies 21659 1Adalimumab therapy effective in AS RA and PsA patients refractory to other anti TNF therapies 21659 2
...c. (Nasdaq: AFFX) and bioMerieux announced today t...d comprehensive access to its GeneChip(R) technolo... for breast cancer, as well as an option to expand...ement, made under the Powered by Affymetrix(TM) pr...fymetrix, patented arrays, instrumentation systems...
...abies fatalities in the United States stem from ba...abies. In 1990, raccoons topped the list of most o... of rabies depends on predicting the spatial dynam...ur and how the virus might spread. In a new study ...oS Biology, Real and colleagues apply a mathematic...
...ears to protect against cancer by affecting a "pro...already targeting in an effort to develop a new dr...ty of Rochester Medical Center have found. The res...enefits of green tea with solid scientific evidenc...sis produced by a student at the university,s Scho...
... North Carolina at Chapel Hill researchers have ma...treatment of liver-based genetic defects such as h...em cells treated in culture with a growth factor a...hemophilia in mice analogous to hemophilia B in hu...ppears in the journal Proceedings of the National ...
Other Biology News:Rabies spread speeds up 2While on trail of dioxin, scientists pinpoint cancer target of green tea 2While on trail of dioxin, scientists pinpoint cancer target of green tea 3Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers 2Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers 3
QML offers standard and customized paraffin embedded tissue blocks.
Services include: ,ISH Protocol Development ,Probe Titer and Optimal Conditions Analyses ,RNA and DNA Screenings in Animal or Human Cells and Tissues ,Double Labeling of RNA / Protein in Cells and Ti
This service involves the optimization of immunostaining. The optimization includes titration of the primary antibody, selection and optimization of secondary reagents (e.g. Alk. Phos., HRP, fluores
Request Info
Biology Products: